• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

(R)-2-hydroxyglutarate drives immune quiescence in the tumor microenvironment of IDH-mutant gliomas.

作者信息

Richardson Leland G, Choi Bryan D, Curry William T

机构信息

Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

出版信息

Transl Cancer Res. 2019 Mar;8(Suppl 2):S167-S170. doi: 10.21037/tcr.2019.01.08.

DOI:10.21037/tcr.2019.01.08
PMID:30956952
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6448779/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/776a/8798193/35116f6642c5/tcr-08-S2-S167-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/776a/8798193/35116f6642c5/tcr-08-S2-S167-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/776a/8798193/35116f6642c5/tcr-08-S2-S167-f1.jpg

相似文献

1
(R)-2-hydroxyglutarate drives immune quiescence in the tumor microenvironment of IDH-mutant gliomas.（R）-2-羟基戊二酸在异柠檬酸脱氢酶（IDH）突变型胶质瘤的肿瘤微环境中驱动免疫静止。
Transl Cancer Res. 2019 Mar;8(Suppl 2):S167-S170. doi: 10.21037/tcr.2019.01.08.
2
D-2-Hydroxyglutarate Is an Intercellular Mediator in IDH-Mutant Gliomas Inhibiting Complement and T Cells.D-2-羟戊二酸是 IDH 突变型神经胶质瘤中的一种细胞间介质，可抑制补体和 T 细胞。
Clin Cancer Res. 2018 Nov 1;24(21):5381-5391. doi: 10.1158/1078-0432.CCR-17-3855. Epub 2018 Jul 13.
3
Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas.2-羟戊二酸磁共振波谱在新诊断的脑肿块和疑似复发性脑胶质瘤中的诊断准确性。
Neuro Oncol. 2018 Aug 2;20(9):1262-1271. doi: 10.1093/neuonc/noy022.
4
IGFBP2 expression predicts IDH-mutant glioma patient survival.胰岛素样生长因子结合蛋白2（IGFBP2）的表达可预测异柠檬酸脱氢酶（IDH）突变型胶质瘤患者的生存期。
Oncotarget. 2017 Jan 3;8(1):191-202. doi: 10.18632/oncotarget.13329.
5
Epigenetic Reprogramming for Targeting -Mutant Malignant Gliomas.靶向突变型恶性胶质瘤的表观遗传重编程
Cancers (Basel). 2019 Oct 22;11(10):1616. doi: 10.3390/cancers11101616.
6
Tissue 2-Hydroxyglutarate as a Biomarker for Mutations in Gliomas.组织 2-羟戊二酸作为神经胶质瘤突变的生物标志物。
Clin Cancer Res. 2019 Jun 1;25(11):3366-3373. doi: 10.1158/1078-0432.CCR-18-3205. Epub 2019 Feb 18.
7
Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.异柠檬酸脱氢酶突变抑制胶质瘤中STAT1和CD8 + T细胞的积累。
J Clin Invest. 2017 Apr 3;127(4):1425-1437. doi: 10.1172/JCI90644. Epub 2017 Mar 20.
8
Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy.2-羟戊二酸在神经胶质瘤中的积累与生存相关：一项由 3.0 特斯拉磁共振波谱仪进行的研究。
Acta Neuropathol Commun. 2014 Nov 7;2:158. doi: 10.1186/s40478-014-0158-y.
9
Non-invasive detection of 2-hydroxyglutarate in IDH-mutated gliomas using two-dimensional localized correlation spectroscopy (2D L-COSY) at 7 Tesla.在7特斯拉磁场下使用二维局部相关光谱法（2D L-COSY）对异柠檬酸脱氢酶（IDH）突变型胶质瘤中的2-羟基戊二酸进行无创检测。
J Transl Med. 2016 Sep 22;14(1):274. doi: 10.1186/s12967-016-1035-1.
10
IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.异柠檬酸脱氢酶（IDH）突变型胶质瘤通过下调自然杀伤细胞2D型受体（NKG2D）配体的表达来逃避自然杀伤细胞的免疫监视。
Neuro Oncol. 2016 Oct;18(10):1402-12. doi: 10.1093/neuonc/now061. Epub 2016 Apr 25.

引用本文的文献

1
Association between autologous formalin-fixed tumor vaccine (AFTV) therapy, molecular pathological markers, and survival outcomes in glioblastoma.自体福尔马林固定肿瘤疫苗（AFTV）治疗、分子病理标志物与胶质母细胞瘤生存结果之间的关联
Brain Tumor Pathol. 2025 Aug 7. doi: 10.1007/s10014-025-00507-1.
2
A Review of Emerging Immunotherapeutic Strategies for IDH-Mutant Glioma.异柠檬酸脱氢酶（IDH）突变型胶质瘤新兴免疫治疗策略综述
Cancers (Basel). 2025 Jun 27;17(13):2178. doi: 10.3390/cancers17132178.
3
Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma.

本文引用的文献

1
Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate.抑瘤代谢产物（R）-2-羟基戊二酸抑制抗肿瘤 T 细胞免疫。
Nat Med. 2018 Aug;24(8):1192-1203. doi: 10.1038/s41591-018-0095-6. Epub 2018 Jul 9.
2
IDH mutational status and the immune system in gliomas: a tale of two tumors?胶质瘤中的异柠檬酸脱氢酶（IDH）突变状态与免疫系统：两种肿瘤的故事？
Transl Cancer Res. 2017 Oct;6(Suppl 7):S1253-S1256. doi: 10.21037/tcr.2017.09.37. Epub 2017 Sep 18.
3
Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.
突变 IDH 调节恶性神经胶质瘤中的抑制性髓系群体。
Clin Cancer Res. 2024 Sep 13;30(18):4068-4076. doi: 10.1158/1078-0432.CCR-24-1056.
4
Characterization of purinergic signaling in tumor-infiltrating lymphocytes from lower- and high-grade gliomas.低级别和高级别脑胶质瘤肿瘤浸润淋巴细胞中嘌呤能信号的特征。
Purinergic Signal. 2024 Feb;20(1):47-64. doi: 10.1007/s11302-023-09931-4. Epub 2023 Mar 24.
5
Tumor Microenvironment in Gliomas: A Treatment Hurdle or an Opportunity to Grab?胶质瘤中的肿瘤微环境：治疗障碍还是可把握的机遇？
Cancers (Basel). 2023 Feb 7;15(4):1042. doi: 10.3390/cancers15041042.
6
Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications.基于新型微环境的肝内胆管癌分类及其治疗意义。
Gut. 2023 Apr;72(4):736-748. doi: 10.1136/gutjnl-2021-326514. Epub 2022 May 18.
7
Metabolomics and the Multi-Omics View of Cancer.代谢组学与癌症的多组学视角
Metabolites. 2022 Feb 7;12(2):154. doi: 10.3390/metabo12020154.
8
Simultaneous high PD-L1 and low VEGFR2 expression is associated with better overall survival in rectal cancer.同时高表达程序性死亡受体配体1（PD-L1）和低表达血管内皮生长因子受体2（VEGFR2）与直肠癌更好的总生存期相关。
Transl Cancer Res. 2021 Jan;10(1):499-508. doi: 10.21037/tcr-20-3106.
9
Identification of a novel pyroptosis-related gene signature correlated with the prognosis of diffuse glioma patients.一种与弥漫性胶质瘤患者预后相关的新型焦亡相关基因特征的鉴定。
Ann Transl Med. 2021 Dec;9(24):1766. doi: 10.21037/atm-21-6011.
10
Microenvironmental Metabolites in the Intestine: Messengers between Health and Disease.肠道中的微环境代谢产物：健康与疾病之间的信使
Metabolites. 2022 Jan 7;12(1):46. doi: 10.3390/metabo12010046.
异柠檬酸脱氢酶突变型脑胶质瘤：不断演变的临床和治疗意义。
Cancer. 2017 Dec 1;123(23):4535-4546. doi: 10.1002/cncr.31039. Epub 2017 Oct 5.
4
Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.异柠檬酸脱氢酶突变作为胶质瘤的治疗靶点。
Chin Clin Oncol. 2017 Jun;6(3):33. doi: 10.21037/cco.2017.06.11.
5
Correlation of immune phenotype with IDH mutation in diffuse glioma.弥漫性胶质瘤免疫表型与 IDH 突变的相关性。
Neuro Oncol. 2017 Oct 19;19(11):1460-1468. doi: 10.1093/neuonc/nox054.
6
Mutant IDH1 regulates the tumor-associated immune system in gliomas.突变型异柠檬酸脱氢酶1（IDH1）调节神经胶质瘤中的肿瘤相关免疫系统。
Genes Dev. 2017 Apr 15;31(8):774-786. doi: 10.1101/gad.294991.116. Epub 2017 May 2.
7
Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.异柠檬酸脱氢酶突变抑制胶质瘤中STAT1和CD8 + T细胞的积累。
J Clin Invest. 2017 Apr 3;127(4):1425-1437. doi: 10.1172/JCI90644. Epub 2017 Mar 20.
8
Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study.复发性高级别胶质瘤患儿接种胶质瘤相关抗原肽疫苗后的抗原特异性免疫反应及临床结果：一项试点研究的结果
J Neurooncol. 2016 Dec;130(3):517-527. doi: 10.1007/s11060-016-2245-3. Epub 2016 Sep 13.
9
Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase.对异柠檬酸脱氢酶突变的胶质瘤患者脑脊液中2-羟基戊二酸D-对映体的选择性检测
Clin Cancer Res. 2016 Dec 15;22(24):6256-6265. doi: 10.1158/1078-0432.CCR-15-2965. Epub 2016 Jun 23.
10
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.2016 年世界卫生组织中枢神经系统肿瘤分类：概述。
Acta Neuropathol. 2016 Jun;131(6):803-20. doi: 10.1007/s00401-016-1545-1. Epub 2016 May 9.